Last reviewed · How we verify
A Phase I Clinical Study, Multiple Dose of LCB01-0371 in Healthy Male Subjects
The purpose of this study is to investigate the population pharmacokinetics of LCB01-0371 after a multiple oral dose in healthy male subjects. To investigate safety, tolerability of LCB01-0371 after a multiple oral dose in healthy male subjects.
Details
| Lead sponsor | LigaChem Biosciences, Inc. |
|---|---|
| Phase | Phase 1 |
| Status | COMPLETED |
| Enrolment | 30 |
| Start date | 2014-06 |
| Completion | 2015-01 |
Conditions
- Healthy
Interventions
- LCB01-0371 800mg
- LCB01-0371 800mg BID
- LCB01-0371 1200mg BID
- Placebo
Primary outcomes
- No of Adverse events — From date of randomization until follow up after 3 days from last hospital discharge
Countries
South Korea